Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

被引:690
作者
Parker, C. [1 ]
Castro, E. [2 ]
Fizazi, K. [3 ]
Heidenreich, A. [4 ]
Ost, P. [5 ]
Procopio, G. [6 ]
Tombal, B. [7 ]
Gillessen, S. [8 ,9 ,10 ]
机构
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Virgen Victoria Univ Hosp, Inst Biomed Res Malaga, Dept Med Oncol, Malaga, Spain
[3] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[4] Univ Hosp Cologne, Dept Urol Urooncol Robot Assisted & Specialized U, Cologne, Germany
[5] Ghent Univ Hosp, Dept Radiat Oncol, Ghent, Belgium
[6] Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol 1, Milan, Italy
[7] Catholic Univ Louvain, Inst Rech Clin, Brussels, Belgium
[8] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[9] USI, Fac Biomed Sci, Lugano, Switzerland
[10] Univ Manchester, Div Canc Med, Manchester, Lancs, England
关键词
chemotherapy; hormone therapy; prostate cancer; radiotherapy; surgery; ANDROGEN-DEPRIVATION THERAPY; ACETATE PLUS PREDNISONE; RADICAL PROSTATECTOMY; RADIATION-THERAPY; OPEN-LABEL; ADJUVANT RADIOTHERAPY; CONSENSUS CONFERENCE; INCREASED SURVIVAL; PHASE-II; DOCETAXEL;
D O I
10.1016/j.annonc.2020.06.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:1119 / 1134
页数:16
相关论文
共 108 条
[31]  
[Anonymous], 2019, EUR UROL
[32]  
[Anonymous], 2018, J CLIN ONCOL, DOI DOI 10.1200/JCO.2017.74.1173
[33]  
[Anonymous], 2018, EUR J CANCER, DOI DOI 10.1016/J.EJCA.2018.08.010
[34]  
[Anonymous], 2015, P AM SOC CLIN ONCO S
[35]  
[Anonymous], 2014, J CLIN ONCOL, DOI DOI 10.1200/JCO.2013.54.7893
[36]  
[Anonymous], 2017, NEW ENGL J MED, DOI DOI 10.1056/NEJMOA1702900
[37]  
[Anonymous], 2007, J CLIN ONCOL, DOI DOI 10.1200/JCO.2007.10.6450
[38]  
[Anonymous], 2016, LANCET ONCOL, DOI DOI 10.1016/S1470-2045(16)30491-0
[39]  
[Anonymous], 2019, JAMA ONCOL, DOI DOI 10.1001/JAMAONCOL.2018.5801
[40]  
[Anonymous], 2016, LANCET ONCOL, DOI DOI 10.1016/S1470-2045(16)00107-8